The mouse models elucidated an important role for reduced Gfi1 expression and the expression of GFI1-36N SNP variant in the accelerated onset of fatal myeloid proliferative disease (MPS) and increased the risk for AML progression [6,7,14,15]. The gene discussed is GFI1; the disease is acute myeloid leukemia.